Last reviewed · How we verify

GSK3511294 (Depemokimab) — Competitive Intelligence Brief

GSK3511294 (Depemokimab) (GSK3511294 (Depemokimab)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-4 receptor alpha antagonist. Area: Immunology.

phase 3 IL-4 receptor alpha antagonist IL-4Rα (Interleukin-4 receptor alpha) Immunology Biologic Live · refreshed every 30 min

Target snapshot

GSK3511294 (Depemokimab) (GSK3511294 (Depemokimab)) — GlaxoSmithKline. Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK3511294 (Depemokimab) TARGET GSK3511294 (Depemokimab) GlaxoSmithKline phase 3 IL-4 receptor alpha antagonist IL-4Rα (Interleukin-4 receptor alpha)
Tabirafusp tedromer Tabirafusp tedromer Kodiak Sciences Inc phase 3 IL-4 receptor alpha antagonist IL-4Rα

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-4 receptor alpha antagonist class)

  1. GlaxoSmithKline · 1 drug in this class
  2. Kodiak Sciences Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK3511294 (Depemokimab) — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk3511294-depemokimab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: